BiotechTube

Etrumadenant (AB928) + FOLFOX regimen + Zimberelimab (AB122)

Phase 2Recruiting
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rectal Cancer

Conditions

Rectal Cancer

Trial Timeline

Mar 31, 2022 → Dec 1, 2030

NCT ID
NCT05024097

About Etrumadenant (AB928) + FOLFOX regimen + Zimberelimab (AB122)

Etrumadenant (AB928) + FOLFOX regimen + Zimberelimab (AB122) is a phase 2 stage product being developed by Arcus Biosciences for Rectal Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05024097. Target conditions include Rectal Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05024097Phase 2Recruiting

Competing Products

20 competing products in Rectal Cancer

See all competitors
ProductCompanyStageHype Score
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
52
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
52
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
25
ALIMTA + OxaliplatinEli LillyPhase 2
52
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
Bevacizumab + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 1/2
41
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
52
FOLFIRI + FOLFOX-4 + FOLFIRI-HD + FOLFOX-7 + FOLFIRINOXChugai PharmaceuticalPhase 2/3
65
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
CPT-11 and TS-1 + CPT-11, 5-FU and l-LVDaiichi SankyoPhase 2/3
65
CPT-11 based regimensDaiichi SankyoPre-clinical
23
CS7017 + irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)Daiichi SankyoPhase 2
52
Tivantinib + Placebo + Cetuximab + IrinotecanDaiichi SankyoPhase 1/2
41
DS-8201a 5.4 mg/kg Q3W + DS-8201a 6.4 mg/kg Q3WDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
CS-1008 + irinotecanDaiichi SankyoPhase 2
52
CS-7017 + PlaceboDaiichi SankyoPhase 2
52
Patritumab DeruxtecanDaiichi SankyoPhase 2
52
CS-1008 + FOLFIRIDaiichi SankyoPhase 1
33
DS-8273a + nivolumabDaiichi SankyoPhase 1
33

Other Products from Arcus Biosciences

Casdatifan + Cabozantinib + PlaceboPhase 3
72
Quemliclustat + Placebo + Nab-paclitaxel + GemcitabinePhase 3
72
Zimberelimab + Domvanalimab + FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)Phase 2
47
Zimberelimab + DomvanalimabPhase 2
47
Zimberelimab + Domvanalimab + EtrumadenantPhase 2
47